Current role of ischemia-modified albumin in routine clinical practice

Biomarkers

Volumn 15, Issue 8, 2010, Pages 655-662

  Dominguez Rodriguez, Alberto ^a   Abreu Gonzalez, Pedro ^b  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^b UNIVERSIDAD DE LA LAGUNA   (Spain)

Author keywords

Acute coronary syndrome; Acute myocardial ischemia; Chest pain; Emergency department

Indexed keywords

BIOLOGICAL MARKER; CHOLINE; FATTY ACID; ISCHEMIA MODIFIED ALBUMIN; TROPONIN I; TROPONIN T;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ATHEROSCLEROTIC PLAQUE; BIBLIOGRAPHIC DATABASE; CLINICAL PRACTICE; ELECTROCARDIOGRAM; GLYCEMIC CONTROL; HEART MUSCLE ISCHEMIA; HUMAN; LUNG EMBOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THORAX PAIN; UNSTABLE ANGINA PECTORIS;

BIOLOGICAL MARKERS; HUMANS; MYOCARDIAL ISCHEMIA; SENSITIVITY AND SPECIFICITY; SERUM ALBUMIN;

EID: 78649252746     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2010.513449     Document Type: Review

References (60)

1. Anwaruddin S, Januzzi JL Jr, Baggish AL, Lewandrowski EL, Lewandrowski KB. (2005). Ischemia modified albumin improves the usefulness of standard cardiac biomarkers for the diagnosis of myocardial ischemia in the emergency department setting. Am J ClinPathol 123:140-5.
2. Aparci M, Kardesoglu E, Ozmen N, Ozcan O, Cebeci BS, Cingozbay BY, Dincturk M. (2007). Prognostic significance of ischemia-modified albumin in patients with acute coronary syndrome. Coron Artery Dis 18:367-73.
3. Apple FS, Wu AH, Mair J, Ravkilde J, Panteghini M, Tate J, Pagani F, Christenson RH, Mockel M, Danne O, Jaffe AS; Committee on Standardization of Markers of Cardiac Damage of the IFCC. (2005). Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. ClinChem 51:810-24. (Pubitemid 40577917)
4. Bar-Or D, Lau E, Winkler JV. (2000). Novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia - a preliminary report. J Emerg Med 19:311-15.
5. Beetham R, Monk C, Keating L, Benger JR, Kendall J. (2006). Effects of storage at - 20 degrees C on ischemia-modified albumin results. Ann ClinBiochem 43:500-2.
6. Bhagavant NV, Lai EM, Rios PA, Yang J, Ortega-Lopez AM, Shinoda H, Honda SAA, Rios CN, Sugiyama CE, Ha CE. (2003). Evaluation on human serum albumin cobalt binding assay for the assessment of myocardial ischemia and myocardial infarction. Clin Chem 49:581-5.
7. Borderie D, Allanore Y, Meune C, Devaux JY, Ekindjian OG, Kahan A. (2004). High ischemia-modified albumin concentration reflects oxidative stress but not myocardial involvement in systemic sclerosis. ClinChem 50:2190-3.
8. Can M, Demirtas S, Polat O, Yildiz A. (2006). Evaluation of effects of ischaemia on the albumin cobalt binding (ACB) assay in patients exposed to trauma. Emerg Med J 23:537-9.
9. Christenson RH, Azzazy HME. (1998). Biochemical markers of the acute coronary syndromes. ClinChem 44:1855-64.
10. Christenson RH, Duh SH, Sanhai WR, Wu AH, Holtman V, Painter P, Branham E, Apple FS, Murakami M, Morris DL. (2001). Characteristics of an Albumin Cobalt Binding Test for assessment of acute coronary syndrome patients: a multicenter study. ClinChem 47:464-70.
11. Collinson PO, Gaze DC. (2007). Biomarkers of cardiovascular damage. Med PrincPract 16:247-61.
12. Collinson PO, Gaze DC, Bainbridge K, Morris F, Morris B, Price A, Goodacre S. (2006). Utility of admission cardiac troponin and 'Ischemia Modified Albumin' measurements for rapid evaluation and rule out of suspected acute myocardial infarction in the emergency department. Emerg Med J 23:256-61.
13. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez MJ, Samimi-Fard S, Kaski JC. (2008a). Relation of ischemia-modified albumin levels and left ventricular systolic function in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. ClinChimActa 388:196-9.
14. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez MJ, Samimi-Fard S, Reiter RJ, Kaski JC. (2008b). Association of ischemia-modified albumin and melatonin in patients with ST-segment elevation myocardial infarction. Atherosclerosis 199:73-8.
15. Dominguez-Rodriguez A, Abreu-Gonzalez P, Jimenez-Sosa A, Samimi-Fard S, Idaira HB. (2009a). Does ischemia-modified albumin add prognostic value to the Trombolysis In Myocardial Infarction risk score in patients with ST-segment elevation myocardial infarction treated with primary angioplasty? Biomarkers 14:43-8.
16. Dominguez-Rodriguez A, Kaski JC, Abreu-Gonzalez P, Samimi-Fard S. (2009b). Role of ischemia modified albumin to ST-segment resolution after mechanical reperfusion in patients with ST-segment elevation myocardial infarction. Atherosclerosis 203:576-80.
17. Duseja R, Feldman JA. (2004). Missed acute cardiac ischemia in the ED: limitations of diagnostic testing. Am J Emerg Med 22:219-25.
18. Fagan GJ, Wayment H, Morris DL, Crosby PA. (2002). The albumin cobalt binding test: analytical performance of a new automated chemistry assay for the detection of ischemia modified albumin (IMA). J Clin Ligand Assay 25:178-87.
19. Falkensammer J, Stojakovic T, Huber K, Hammerer-Lercher A, Gruber I, Scharnagl H, Fraedrich G, Santner W, Schocke M, Greiner A. (2007). Serum levels of ischemia-modified albumin in healthy volunteers after exercise-induced calf-muscle ischemia. ClinChem Lab Med 45:535-40.
20. Garrido IP, Roy D, Calviño R, Vazquez-Rodriguez JM, Aldama G, Cosin-Sales J, Quiles J, Gaze DC, Kaski JC. (2004). Comparison of ischemia-modified albumin levels in patients undergoing percutaneous coronary intervention for unstable angina pectoris with versus without coronary collaterals. Am J Cardiol 93:88-90.
21. Gaze DC. (2009). Ischemia modified albumin: a novel biomarker for the detection of cardiac ischemia. Drug MetabPharmacokinet 24:333-41.
22. Gaze DC, Crompton L, Collinson P. (2006). Ischemia-modified albumin concentrations shuold be interpreted with caution in patients with low serum albumin concentrations. Med PrincPract 15:322-4.
23. ® plus analyzer. ClinChem Lab Med 42:455-61.
24. Govender R, De Greef J, Delport R, Becker PJ, Vermaak WJ. (2008). Biological variation of ischemia-modified albumin in healthy subjects. Cardiovasc J Afr 19:141-4.
25. Hakligor A, Kosem A, Senes M, Yucel D. (2010). Effect of albumin concentration and serum matriz on ischemia-modified albumin. ClinBiochem 43:345-8.
26. Hjortshøj S, Kristensen SR, Ravkilde J. (2010). Diagnostic value of ischemia-modified albumin in patients with suspected acute coronary syndrome. Am J EmergMed 28:170-6.
27. Iuliano L, Pratico D, Greco C, Mangieri E, Scibilia G, FitzGerald GA, Violi F. (2001). Angioplasty increases coronary sinus F2-isoprostane formation: evidence for in vivo oxidative stress during PTC. J Am CollCardiol 37:76-80.
28. Jalan R, Schnurr K, Moorkerjee RP, Chshire L, Hodges S, Muravsky V, Williamns R, Matthes G, Davies NA. (2009). Alteration in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increase mortality. Hepatology 50:555-64.
29. Keating L, Benger JR, Beetham R, Bateman S, Veysey S, Kendall J, Pullinger R. (2006). The PRIMA study: presentation ischaemiamodified albumin in the emergency department. Emerg Med J 23:764-8.
30. Lee YW, Kim HJ, Shin HB, Choi TY, Lee YK. (2007). Application of albumin-adjusted ischemia modified albumin index as an early screening marker for acute coronary syndrome. ClinChimActa 384:24-7.
31. Libby P. (2001). Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 104:365-72.
32. Lippi G, Montagnana M, Guidi GC. (2006a). Albumin cobalt binding and ischemia modified albumin generation: an endogenous response to ischemia? Int J Cardiol 108:410-11.
33. Lippi G, Montagnana M, Salvagno G, Guidi GC. (2006b). Potential value for new diagnostic markers in the early recognition of acute coronary syndromes. CJEM 8:27-31.
34. Lippi G, Montagnana M, Salvagno G, Guidi GC. (2007). Standarization of ischemia-modified-albumin testing: adjunstement for serum albumin. ClinChem Lab Med 45:261-2.
35. Ming-Hui Lin R, Fatovich DM, Grasko JM, Vasikaran SD. (2010). Ischaemia modified albumin cannot be used for rapid exclusion of acute coronary syndrome. Emerg Med J [Epub ahead of print].
36. Morrow DA, de Lemos JA, Sabatine MS, Antman EM. (2003). The search for a biomarker of cardiac ischemia. Clin Chem 49:537-9.
37. Pantazopoulos I, Papadimitriou L, Dontas I, Demestiha T, Lakovidou N, Xanthos T. (2009). Ischaemia modfed albumin in the diagnosis of acute coronary syndromes. Resuscitation 80:306-10.
38. Peacock F, Morris DL, Anwaruddin S, Christenson RH, Collinson PO, Goodacre SW, Januzzi JL, Jesse RL, Kaski JC, Kontos MC, Lefevre G, Mutrie D, Sinha MK, Uettwiller-Geiger D, Pollack CV. (2006). Meta-analysis of ischemia-modified albumin to rule out acute coronary syndromes in the emergency department. Am Heart J 152:253-62.
39. Piwowar A, Knapik-Kordecka M, Warwas M. (2008). Ischemiamodified albumin level in type 2 diabetes mellitus - Preliminary report. Dis Markers 24:311-17.
40. Pope JH, Aufderheide TP, Ruthazer R, Woolard RH, Feldman JA, Beshansky JR, Griffith JL, Selker HP. (2000). Missed diagnoses of acute cardiac ischemia in the emergency department. N Engl J Med 342:1163-70.
41. Quiles J, Roy D, Gaze D, Garrido IP, Avanzas P, Sinha M, Kaski JC. (2003) Relation of ischemia-modified albumin (IMA) levels following elective angioplasty for stable angina pectoris to duration of balloon-induced myocardial ischemia. Am J Cardiol 92:322-4.
42. Rajappa M, Sharma A. (2005). Biomarkers of cardiac injury: an update. Angiology 56:677-91.
43. Roy D, Quiles J, Aldama G, Sinha M, Avanzas P, Arroyo-Espliguero R, Gaze D, Collinson P, Carlos Kaski J. (2004a). Ischemia modified albumin for the assessment of patients presenting to the emergency department with acute chest pain but normal or non-diagnostic 12-lead electrocardiograms and negative cardiac troponin T. Int J Cardiol 97:297-301.
44. Roy D, Quiles J, Sharma R, Sinha M, Avanzas P, Gaze D, Kaski JC. (2004b). Ischemia-modified albumin concentrations in patients with peripheral vascular disease and exercise-induced skeletal muscle ischemia. ClinChem 50:1656-60.
45. Roy D, Quiles J, Sinha M, Aldama G, Gaze D, Kaski JC. (2004c). Effect of direct-current cardioversion on ischemia-modified albumin levels in patients with atrial fibrillation. Am J Cardiol 93:366-8.
46. Roy D, Quiles J, Sinha M, Floros D, Gaze D, Collinson P, Baxter G F, Kaski JC. (2004d). Effect of radiofrequency catheter ablation on the biochemical marker ischemia modified albumin. Am J Cardiol 94:234-6.
47. Ryan TJ, Anderson JL, Antman EM, Braniff BA, Brooks NH, Califf RM, Hillis LD, Hiratzka L F, Rapaport E, Riegel BJ, Russell RO, Smith EE Jr, Weaver WD. (1996). ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Managementof Acute Myocardial Infarction). J Am CollCardiol 28:1328-428.
48. Sbarouni E, Georgiadou P, Panagiotakos D, Alivizatos PA, Voudris V. (2009). Increased ischaemia modified albumin following coronary artery bypass grafting. Biomarkers 14:38-42.
49. Sbarouni E, Georgiadou P, Manginas A, Panagiotakos D, Karavolias GK, Voudris V. (2010). Ischaemia-modified albumin in pulmonary hypertension. Biomarkers 15:238-42.
50. Sinha MK, Gaze Dc, Tippins JR, Collinson PO, Kaski JC. (2003). Ischemia modified albumin is a sensitive marker of myocardial ischemia after percutaneous coronary intervention. Circulation 107:2403-5.
51. Sinha MK, Roy D, Gaze DC, Collinson PO, Kaski JC. (2004). Role of "ischemia modified albumin", a new biochemical marker of myocardial ischemia, in the early diagnosis of acute coronary syndromes. Emerg Med J 21:29-34.
52. Sinha MK, Vasquez JM, Calvino R, Gaze DC, Collinson PO, Kaski JC. (2006). Effects of balloon occlusion during percutaneous coronary intervention on circulating ischemia modified albumin and transmyocardial lactate extraction. Heart 92:1852-3.
53. Storrow AB, Gibler WB. (2000). Chest pain centers: diagnosis of acute coronary syndromes. Ann Emerg Med 35:449-61.
54. Toutouzas K, Stefanadis C. (2006). Advances in vulnerable plaque detection and treatment: how far have we gone? Hellenic J Cardiol 47:129-31.
55. Turedi S, Gunduz A, Mentese A, Karahan SC, Yilmaz SE, Eroglu O, Nuhoglu I, Turan I, Topbas M. (2007) Value of ischemia-modified albumin in the diagnosis of pulmonary embolism. Am J Emerg Med 25:770-3.
56. Turedi S, Gunduz A, Mentese A, Topbas M, Karahan SC, Yeniocak S, Turan I, Eroglu O, Ucar U, Karaca Y, Turkmen S, Russell RM. (2008). The value of ischemia-modified albumin compared with d-dimer in the diagnosis of pulmonary embolism. Respir Res 9:49.
57. Turedi S, Patan T, Gunduz A, Mentese A, Thekinbas C, Topbas M, Karahan SC, Yulug E, Turkmen S, Ucar U. (2009). Ischemiamodified albumin in the diagnosis of pulmonary embolism: an experimental study. Am J Emerg Med 27:635-40.
58. Van Belle E, Dallongeville J, Vicaut E, Degrandsart A, Baulac C, Montalescot G;, OPERA Investigators. (2010). Ischemia-modified albumin levels predict long-term outcome in patients with acute myocardial infarction. The French Nationwide OPERA study. Am Heart J 159:570-6.
59. Worster A, Devereaux PJ, Heels-Ansdell D, Guyatt GH, Opie J, Mookadam F, Hill SA. (2005). Capability of ischemia-modified albumin to predict serious cardiac outcomes in the short term among patients with potential acute coronary syndrome. CMAJ 172:1685-90.
60. Zapico-Muñiz E, Santaló-Bel M, Mercé-Muntañola J, Montiel JA, Martínez-Rubio A, Ordóñez-Llanos J. (2004). Ischemia-modified albumin during skeletal muscle ischemia. Clin Chem 50:1063-5.